On Monday, the Food and Drug Administration announced a new warning on the single-dose Johnson and Johnson COVID vaccine.
The CDC said around 12.8 million doses of the Johnson & Johnson vaccine have been administered in the United States. Out of those, about 100 preliminary reports of Guillain-Barré Syndrome have been detected.
Health officials are saying the benefits of the shot outweigh the risk.
Guillain-Barré Syndrome is a rare condition in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis.
The FDA said in most of these people, symptoms began within 42 days of receiving their Johnson & Johnson dose.
Officials say this new warning shouldn’t discourage anyone from taking the one-dose shot.
In a statement, Johnson & Johnson said the safety and well-being of the people who use their products is the company’s number one priority. The company also added the chance of having this side-effect is very low.